World hepatitis day on Monday.... Would be a good day!
“The pace of patient accrual for the ARC-520 Phase 2a study has been very encouraging with the first dose group being enrolled and dosed in just over a week,” said Christopher Anzalone, Ph.D., Arrowhead’s President and CEO. “According to the study protocol, we expect to begin dosing the next cohort in May and remain confident that we can release top line data in the third quarter. ARC-520 has the potential to be the first drug candidate ever to demonstrate consistent hepatitis B surface antigen reduction in humans, which is thought to be critical in achieving a functional cure for chronic HBV.”
If only we could report like that.
BLT Price at posting:
$1.08 Sentiment: Buy Disclosure: Held
